SMNR — Semnur Pharmaceuticals Share News
0.000.00%
- $139.36m
- $142.35m
Brief: Denali Capital Acquisition Corp Announces Extension Of Deadline To Complete Initial Business Combination
Brief: Denali Capital Acquisition Announces Intention To Extend Deadline To Complete An Initial Business Combination
Brief: Denali Capital Acquisition Corp. Announces Extension Of Deadline To Complete An Initial Business Combination
Brief: Denali Capital Acquisition Corp Announces Extension Of Deadline To Complete Initial Business Combination
Brief: Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination To Create Nasdaq-Listed Biopharmaceutical Company Focused On Advancing New Technologies To Promote Human Health And Longevity